Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer
NCT00039455 · National Cancer Institute (NCI) · PHASE1 · terminated · last registry update 2013-02-01 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Administratively complete.” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ERBB2 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2013-12-06Phase 3 first posted: National Cancer Institute (NCI), Aromatase Inhibition Therapy + Carboplatin (NCT02003209)
- 2013-01-21Phase 3 first posted: Hoffmann-La Roche, trastuzumab + trastuzumab emtansine (NCT01772472)
- 2012-02-03Phase 3 first posted: Cancer Trials Ireland, Trastuzumab + Paclitaxel (NCT01526369)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision